[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase
by 5% (CER) in first half of 2024; strong growth in second quarter
– full-year earnings outlook raised
- Group sales were up by 5%1 at
constant exchange rates (CER) (stable in CHF) in the first half,
driven by the high demand for both our medicines and diagnostics;
excluding COVID-19-related products, sales increased by 8%
- Group sales growth accelerated to 9% (7% in
CHF) in the second quarter as the decline in COVID-19-related sales
no longer had an impact on overall sales
- Pharmaceuticals Division
sales rose by 5% in the first half; strong growth
of 8% in the base business2 excluding
COVID-19 effect was driven by continued high demand for our newer
medicines to treat severe diseases; eye medicine Vabysmo was again
the major growth driver
- Diagnostics Division sales rose by 5%, while
growth in the base business2, which
excludes the impact of COVID-19 sales, was 9% due to higher demand
for immunodiagnostic products
- Core operating profit increased by 11% (4% in
CHF), core earnings per share grew by 9% (1% in
CHF) and IFRS net income was down by 4%
- Outlook for 2024 earnings raised
- Highlights:
- US approval for Vabysmo prefilled syringe for
three leading causes of vision loss and PiaSky for
a rare blood condition; US filing acceptance for
Susvimo in two leading causes of vision loss in
adults with diabetes
- US FDA Breakthrough Therapy Designation, priority review and
filing acceptance for inavolisib (breast cancer);
US FDA Breakthrough Therapy Designation for
Columvi (blood cancer)
- EU approval for Ocrevus subcutaneous injection
(multiple sclerosis) and Alecensa (early-stage
lung cancer); positive EU opinion for Vabysmo
(retinal vein occlusion, a severe eye disease) and
PiaSky in paroxysmal nocturnal haemoglobinuria
(PNH), a rare blood condition; EU marketing authorisation
application review initiated for Elevidys
(Duchenne muscular dystrophy)
- Positive phase III data for Columvi (blood
cancer), five-year data for Evrysdi (spinal
muscular atrophy), four-year data for Vabysmo
(DME, a severe eye disease), phase Ib data for
CT-388 (obesity) and phase I data for
CT-996 (obesity)
- CE mark for Accu-Chek SmartGuide, an
AI-enabled continuous glucose monitoring solution offering critical
predictions to people living with diabetes
- US approval of human papillomavirus (HPV)
self-collection solution, the first available in the
country to allow women to privately collect their samples; two new
WHO prequalifications for cervical cancer
screening tools, including HPV self-collection
solution
- Launch of new analytical units, cobas c 703
and cobas ISE neo, to deliver higher testing
capacity and increased automation for laboratories
- US emergency use authorisation for cobas liat
four-in-one molecular test for some of the most prevalent
respiratory viruses
Roche CEO Thomas Schinecker: “Our strong sales
growth in the first half of 2024 reflects the high demand for our
innovative medicines and diagnostics. In the second quarter, we saw
an acceleration of our growth momentum as Group sales were no
longer impacted by the decline in COVID-19 sales, resulting in very
strong sales growth for the Group. Based on our strong half-year
results, we are raising our earnings outlook for the full year.
We also received a number of important regulatory approvals in
the last three months, including EU approval for Alecensa for a
form of early-stage lung cancer, as well as for the subcutaneous
injection of Ocrevus, which provides an additional treatment option
for multiple sclerosis. I am particularly pleased about the US
approval for the ready-to-use prefilled syringe of our eye medicine
Vabysmo, which continues to be our main growth driver. In
diagnostics, our new Accu-Chek SmartGuide solution for continuous
blood glucose monitoring uses artificial intelligence to provide
reliable blood glucose level forecasts for several hours.”
Key figures |
CHF millions |
% change |
January–June |
2024 |
2023 |
At CER1 |
In CHF |
Group sales |
29,848 |
29,779 |
5 |
0 |
Pharmaceuticals Division sales |
22,637 |
22,511 |
5 |
1 |
Diagnostics Division sales |
7,211 |
7,268 |
5 |
-1 |
Core operating profit |
11,293 |
10,911 |
11 |
4 |
Core EPS – diluted (CHF) |
10.23 |
10.10 |
9 |
1 |
IFRS net income |
6,697 |
7,563 |
-4 |
-11 |
Outlook for 2024 earnings raised
Roche expects an increase in Group sales in the
mid single digit range (CER).
Core earnings per share are targeted to grow in
the high single digit range (CER), excluding the impact from the
resolution of tax disputes in 2023.
Roche expects to further increase its dividend
in Swiss francs.
Group results
In the first half of 2024, Group sales were up by
5% at CER (stable in CHF) at CHF 29.8 billion. While the
appreciation of the Swiss franc slowed against most currencies, it
had an adverse impact on the results presented in Swiss francs
compared to constant exchange rates.
Core operating profit grew by 11% (4% in CHF),
driven by higher sales and cost management.
Core earnings per share increased by 9% (1% in
CHF). IFRS net income was 4% lower (-11% in CHF),
mainly due to the impairment of product and technology intangible
assets in the research or development phase following strategic
decisions. In addition, the IFRS result was impacted by the base
effect of the release of provisions related to litigations in the
first half of 2023.
The Pharmaceuticals Division base business grew
by 8%, while divisional sales increased by 5% to
CHF 22.6 billion, driven primarily by higher sales of Vabysmo
(severe eye diseases), with growing demand for Phesgo (breast
cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and
Evrysdi (spinal muscular atrophy). These five medicines together
generated total sales of CHF 7.3 billion, an increase of CHF
1.8 billion (CER) from the first half of 2023.
The eye medicine Vabysmo, launched in early 2022, remained a
major growth driver, generating sales of CHF 1.8 billion on growing
demand in all regions, mainly the US.
Sales of MabThera/Rituxan, Herceptin and Avastin decreased by a
combined CHF 0.4 billion (CER) as the impact of biosimilar
competition slowed further. Sales of the COVID-19 medicine
Ronapreve were minimal compared with CHF 0.5 billion in the first
half of 2023.
In the United States, sales grew by 5% as
increased sales of Vabysmo, Polivy, Ocrevus and Xolair (food
allergies) were partially offset by the continued decline in sales
of medicines for which patent protection has expired. Vabysmo
achieved CHF 1.4 billion in sales, showing a high uptake in both
new patients and patients switching from other medications.
In Europe, sales surged by 10%, driven by
demand for Vabysmo in France, the UK and Germany as well as by the
continued uptake of Phesgo, Ocrevus, Hemlibra (haemophilia) and
Evrysdi. This was partially offset by lower sales of medicines for
which patent protection has expired and of Perjeta (breast cancer)
due to ongoing conversion of patients to Phesgo.
Sales in Japan were down 28%, mainly due to the
base effect of the supply of Ronapreve (COVID-19) to the government
in the first half of 2023. Excluding this effect, sales in Japan
were 5% lower as strong demand for Phesgo was more than offset by
the impact of government price cuts.
Sales in the International region increased by
17%, led by demand for Perjeta, Evrysdi, Phesgo and Tecentriq
(cancer immunotherapy). Sales in China increased
by 14%, driven by Perjeta, Alecensa (lung cancer), Avastin (liver
cancer), Xofluza (influenza) and Polivy.
The Diagnostics Division base business grew by
9%, while divisional sales increased by 5% to CHF
7.2 billion. Immunodiagnostic products, which include cardiac,
oncology and thyroid tests, were the main growth drivers (11%).
Additional growth impetus came from clinical chemistry (8%),
advanced staining techniques in oncology (11%) and from companion
diagnostics (46%).
The continued good growth in the division’s base business was
partially offset by the expected sales decline of COVID-19-related
products. Sales of COVID-19 tests further declined to CHF 0.1
billion in the first half of 2024 from CHF 0.4 billion in the
corresponding period last year.
Sales growth was reported across all regions, with the Europe,
Middle East and Africa (EMEA) region growing by 4%, North America
by 5%, Asia-Pacific by 3% and Latin America by 16%.
Pharmaceuticals: key developments
Compound |
Milestone |
Regulatory |
Susvimo Severe eye disease |
Roche to reintroduce Susvimo in the US for people with
neovascular age-related macular degeneration (nAMD)
- The FDA has approved updates to Susvimo, which will be
available to US retina specialists and patients with nAMD in the
coming weeks
- Susvimo offers the first alternative to regular eye injections
that are standard of care for nAMD, which impacts 20 million people
worldwide and can cause blindness if left untreated
- By continuously delivering medicine to the eye through a
refillable implant, Susvimo is the first and only approved nAMD
treatment shown to maintain vision with two refills a year
More information: Media Release, 8 July 2024 |
Vabysmo prefilled syringe
Severe eye diseases |
FDA approves Vabysmo prefilled syringe (PFS) for three
leading causes of vision loss
- Vabysmo PFS is the first and only syringe prefilled with an
FDA-approved bispecific antibody to treat retinal conditions that
can cause blindness
- Designed to simplify administration, Vabysmo PFS provides
retina specialists a ready-to-use option
- Vabysmo PFS will be available for people living with nAMD, DME
and RVO
More information: Media Release, 5 July 2024 |
Vabysmo
Severe eye diseases |
Vabysmo gets CHMP recommendation for third indication
retinal vein occlusion (RVO)
- Positive recommendation is based on two phase III studies. In
addition to robust retinal drying with Vabysmo, these data show
early and sustained vision improvements, which are non-inferior to
aflibercept
- If approved, Vabysmo would be the first and only bispecific
antibody treatment available for the nearly one million people with
RVO in the European Union
- Vabysmo is already approved in the US and Japan for RVO and in
more than 95 countries around the world for people living with nAMD
and DME
More information: Media Release, 28 June 2024 |
PiaSky Rare blood condition |
CHMP recommends EU approval of PiaSky for people with PNH,
a rare, life-threatening blood condition
- If approved, PiaSky would be the first monthly subcutaneous
(SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in
the EU
- Additionally, with the option of self-administration, PiaSky
may provide an alternative to existing intravenous (IV) C5
inhibitors, potentially helping to reduce treatment burden
- The recommendation is based on the results of the COMMODORE 2
study, where SC PiaSky given every month demonstrated equivalent
disease control and comparable safety to IV eculizumab given every
two weeks
More information: Media Release, 28 June 2024 |
Ocrevus
Multiple sclerosis |
Ocrevus subcutaneous administration approved by European
Commission as first and only twice-a-year injection for relapsing
and primary progressive multiple sclerosis
- Ocrevus subcutaneous (SC) injection offers a new, 10-minute
administration of Ocrevus with comparable efficacy and safety to
intravenous infusion (IV)
- Ocrevus SC provides an additional treatment option without the
need for IV facilities, expanding accessibility for patients
- Roche is working closely with national health systems in Europe
to ensure people with multiple sclerosis can access Ocrevus SC as
quickly as possible
More information: Media Release, 25 June 2024 |
Elevidys
Duchenne muscular dystrophy |
EMA has initiated review of the Elevidys Marketing
Authorisation application for the treatment of Duchenne muscular
dystrophy (DMD)
- If approved, Elevidys is expected to be the first and only gene
therapy available in Europe to address the underlying cause of
Duchenne muscular dystrophy
- Elevidys is already approved in the US, Qatar, Kuwait, UAE,
Oman and Bahrain
More information: Investor Update, 24 June 2024 |
Alecensa Lung cancer
|
European Commission approves Alecensa as the first and only
targeted adjuvant treatment for people with ALK-positive
early-stage lung cancer
- Alecensa reduced the risk of disease recurrence or death by an
unprecedented 76% in people with ALK-positive resected non-small
cell lung cancer (NSCLC), as demonstrated in the phase III ALINA
study
- The approval of Alecensa addresses an urgent unmet need in the
early-stage setting where about half of all people experience
disease recurrence following surgery, despite adjuvant
chemotherapy
- Early diagnosis and treatment of lung cancer can reduce the
burden associated with progressive disease and give people the best
possible chance of cure
More information: Media Release, 10 June 2024 |
Inavolisib
Breast cancer |
FDA grants priority review to inavolisib for advanced
hormone receptor-positive, HER2-negative breast cancer with a
PIK3CA mutation
- Priority review recognises the best-in-class potential of the
inavolisib-based regimen for patients in urgent need of new
treatment options
- Additional analyses of INAVO120 were presented in an oral
abstract session at the 2024 American Society of Clinical Oncology
Annual Meeting
- The target action date for the FDA decision is 27 November
2024
More information: Media Release, 29 May 2024 |
Inavolisib
Breast cancer |
FDA grants Breakthrough Therapy Designation to inavolisib
for advanced hormone receptor-positive, HER2-negative breast cancer
with a PIK3CA mutation
- The designation is based on phase III INAVO120 results, showing
the inavolisib-based regimen more than doubled progression-free
survival compared with palbociclib and fulvestrant alone in the
first-line setting
- Approximately 40% of people with hormone receptor-positive
breast cancer have a PIK3CA mutation and often face poorer
prognosis and resistance to endocrine treatment
- This is the 29th Breakthrough Therapy Designation for Roche’s
oncology portfolio, a testament to our enduring ambition to deliver
transformative medicines for patients
More information: Media Release, 21 May 2024 |
Phase III, pivotal and other key readouts; data
presentations |
Susvimo
Severe eye disease |
New data for Susvimo demonstrate sustained efficacy in two
serious diabetic eye conditions
- Two-year phase III data presented at the 2024 American Society
of Retina Specialists (ASRS) annual meeting show the potential of
Susvimo as an alternative to eye injections to treat diabetic
macular oedema (DME) and diabetic retinopathy (DR)
- Safety data were consistent with the known safety profile for
Susvimo in people with DME and DR
- Additionally, the FDA has accepted the filing application for
Susvimo in DME and DR based on one-year Pagoda and Pavilion study
data
- Susvimo is a unique therapeutic approach that provides
continuous delivery of medicine to the eye through a refillable
implant
More information: Media Release, 18 July 2024 |
Vabysmo
Severe eye diseases |
Vabysmo shows extended durability, continued efficacy and a
consistent safety profile in long-term diabetic macular oedema
(DME) study
- More than 90% of patients had absence of DME after four years
in a pre-specified exploratory endpoint
- People treated with Vabysmo sustained vision gains and
anatomical improvements, with almost 80% receiving treatment at
intervals of three or four months, in an exploratory analysis
- The study met all primary endpoints, showing safety data were
consistent with the known safety profile of Vabysmo
- This is the largest long-term extension dataset in DME to date,
demonstrating consistent positive results in a highly prevalent eye
condition
More information: Media Release, 17 July 2024 |
CT-996
Obesity |
Roche announces positive phase I results for its oral GLP-1
receptor agonist CT-996 for the treatment of people with
obesity
- After four weeks of treatment, CT-996 demonstrated clinically
meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p
< 0.001)
- Pharmacokinetic data support a once-daily oral dosing regimen
for CT-996
- The safety and tolerability profile was consistent with that of
other oral GLP-1 receptor agonists and no unexpected safety signals
were observed
More information: Media Release, 17 July 2024 |
Tiragolumab
Lung cancer |
Update on phase II/III SKYSCRAPER-06 study in metastatic
non-squamous non-small cell lung cancer
- SKYSCRAPER-06, evaluating tiragolumab plus Tecentriq and
chemotherapy, did not meet the primary endpoints of
progression-free survival at primary analysis and overall survival
at first interim analysis
- The combination of tiragolumab plus Tecentriq and chemotherapy
showed reduced efficacy compared to the comparator arm
- Safety was consistent with previous studies; however, Roche
intends to halt the trial due to reduced efficacy compared to the
comparator arm
More information: Media Release, 4 July 2024 |
Columvi
Blood cancer |
Phase III STARGLO study demonstrates Columvi significantly
extends survival in people with relapsed or refractory diffuse
large B-cell lymphoma
- The study met its primary endpoint of overall survival with a
41% reduction in the risk of death in people with relapsed or
refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with
Columvi plus chemotherapy
- This Columvi combination could provide a much-needed
off-the-shelf treatment option for people with
transplant-ineligible R/R DLBCL
- Data were featured in the congress press briefing and presented
in the Plenary Abstracts Session at EHA 2024 as a late-breaking
oral presentation
More information: Media Release, 15 June 2024 |
Evrysdi Spinal muscular atrophy |
Five-year data for Evrysdi show the majority of treated
children with a severe form of spinal muscular atrophy achieved or
maintained the ability to sit, stand or walk
- After five years of treatment, 91% of children were alive —
without treatment, children with type 1 SMA would not be expected
to live past two years of age
- 96% of children treated with Evrysdi could swallow, 80% could
feed without a feeding tube and 59% could sit without support for
at least 30 seconds
- Evrysdi is now approved in more than 100 countries with over
15,000 patients treated globally
More information: Media Release, 7 June 2024 |
CT-388
Obesity
|
Positive phase Ib results for dual GLP-1/GIP receptor
agonist CT-388 in people with obesity
- Over 24 weeks, a once-weekly subcutaneous injection of CT-388
achieved a clinically meaningful and statistically significant mean
placebo-adjusted weight loss of 18.8% (p < 0.001)
- At week 24, 100% of CT-388 treated participants achieved >5%
weight loss, 70% achieved >15% weight loss and 45% achieved
>20% weight loss
- In a subgroup with pre-diabetes at baseline, CT-388 treatment
normalised glycaemia in all patients, indicating its strong impact
on glucose homoeostasis
- No new or unexpected safety signals were detected. Overall,
CT-388 demonstrated a safety and tolerability profile consistent
with its drug class
More information: Media Release, 16 May 2024 |
Pharmaceuticals sales
Sales |
CHF millions |
As % of sales |
% change |
January–June |
2024 |
2023 |
2024 |
2023 |
At CER |
In CHF |
Pharmaceuticals Division |
22,637 |
22,511 |
100.0 |
100.0 |
5 |
1 |
United States |
11,882 |
11,573 |
52.5 |
51.4 |
5 |
3 |
Europe |
4,425 |
4,105 |
19.5 |
18.2 |
10 |
8 |
Japan |
1,366 |
2,210 |
6.0 |
9.8 |
-28 |
-38 |
International* |
4,964 |
4,623 |
22.0 |
20.6 |
17 |
7 |
All figures shown in the table were restated to reflect the
shift of the Foundation Medicine (FMI) business from the
Pharmaceuticals Division to the Diagnostics Division.
*Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia
and Indian subcontinent), Latin America, Middle East, Africa,
Canada, other
Top-selling medicines |
Total |
United States |
Europe |
Japan |
International |
CHF m |
% |
CHF m |
% |
CHF m |
% |
CHF m |
% |
CHF m |
% |
Ocrevus Multiple sclerosis |
3,359 |
8 |
2,411 |
5 |
639 |
12 |
- |
- |
309 |
27 |
Hemlibra Haemophilia A |
2,143 |
7 |
1,231 |
1 |
468 |
14 |
171 |
3 |
273 |
32 |
Perjeta3 Breast cancer |
1,921 |
-2 |
694 |
-7 |
341 |
-16 |
66 |
-30 |
820 |
14 |
Tecentriq Cancer immunotherapy |
1,798 |
2 |
898 |
-8 |
429 |
10 |
182 |
-2 |
289 |
32 |
Vabysmo Eye diseases (nAMD, DME, RVO) |
1,794 |
93 |
1,371 |
78 |
287 |
183 |
53 |
35 |
83 |
324 |
Actemra/RoActemra3 RA,
COVID-19 |
1,276 |
3 |
595 |
6 |
363 |
-3 |
146 |
7 |
172 |
4 |
Xolair3 Asthma |
1,110 |
10 |
1,110 |
10 |
- |
- |
- |
- |
- |
- |
Kadcyla3 Breast cancer |
999 |
6 |
381 |
1 |
288 |
-1 |
46 |
2 |
284 |
23 |
Evrysdi Spinal muscular atrophy |
838 |
25 |
283 |
14 |
286 |
21 |
44 |
14 |
225 |
50 |
Phesgo Breast cancer |
799 |
60 |
258 |
27 |
354 |
51 |
50 |
- |
137 |
115 |
Alecensa Lung cancer |
766 |
7 |
236 |
9 |
145 |
1 |
96 |
4 |
289 |
10 |
Herceptin3 Breast and gastric
cancer |
740 |
-11 |
138 |
-19 |
154 |
-14 |
8 |
-44 |
440 |
-5 |
MabThera/Rituxan3 Blood cancer,
RA |
706 |
-17 |
422 |
-19 |
77 |
-17 |
9 |
-23 |
198 |
-11 |
Avastin 3 Various cancer types |
654 |
-16 |
199 |
-20 |
44 |
-20 |
102 |
-33 |
309 |
-4 |
Activase/TNKase3
Cardiac diseases |
593 |
-2 |
561 |
-3 |
- |
- |
- |
- |
32 |
17 |
Polivy Blood cancer |
513 |
54 |
255 |
112 |
86 |
9 |
92 |
-1 |
80 |
107 |
Gazyva/Gazyvaro3 Blood cancer |
445 |
15 |
217 |
14 |
123 |
13 |
15 |
-16 |
90 |
29 |
Pulmozyme3 Cystic fibrosis |
225 |
-2 |
141 |
-8 |
39 |
2 |
- |
26 |
45 |
20 |
Madopar3 Parkinson’s disease |
200 |
13 |
- |
- |
50 |
1 |
- |
- |
150 |
17 |
CellCept3 Immunosuppressant |
197 |
4 |
12 |
-26 |
60 |
-5 |
18 |
-10 |
107 |
19 |
DME: diabetic macular oedema / nAMD: neovascular or ‘wet’
age-related macular degeneration / RVO: retinal vein occlusion /
RA: rheumatoid arthritis
Diagnostics: key developments
Product |
Milestone |
Accu-Chek SmartGuide
Diabetes management |
CE mark for AI-enabled continuous glucose monitoring
solution offering critical predictions to people living with
diabetes
- The Accu-Chek SmartGuide CGM solution provides accurate
real-time glucose values for adults living with type 1 and type 2
diabetes on flexible insulin therapy
- The built-in AI-trained algorithms will empower users to
proactively intervene when their glucose levels require attention
and before a complication can even occur
- The solution is set to launch in selected European markets in
the coming months
More information: Media Release, 9 July 2024 |
cobas 5800, 6800 and 8800 systems Human
papillomavirus (HPV) |
Roche expands access to cervical cancer screening tools
with two new WHO prequalification designations, including HPV
self-collection
- The World Health Organization (WHO) has awarded Roche’s human
papillomavirus (HPV) test prequalification designations for use on
the cobas 5800 system and for self-collected samples on the cobas
5800, 6800 and 8800 systems
- These designations build upon last June’s WHO prequalification
that included the cobas HPV test for use on the cobas 6800 and 8800
systems
- WHO prequalification enables low- and middle-income countries
(LMICs) to use Roche HPV screening solutions, including
self-collection, in their national cervical cancer elimination
programmes, which will greatly increase access
- Every year, over 600,000 women worldwide are diagnosed with
cervical cancer and over 340,000 die from this preventable disease
caused by HPV infection. Nine out of 10 women who die from cervical
cancer live in LMICs
More information: Media Release, 27 June 2024 |
cobas pro integrated solutions
|
Roche launches new analytical units for cobas pro
integrated solutions delivering greater efficiency and capacity to
laboratories
- The cobas c 703 and cobas ISE neo analytical units deliver
higher testing capacity and increased automation, helping to
improve laboratory workflows and advance patient care
- The new cobas c 703 analytical unit offers industry-leading
high-throughput clinical chemistry testing with up to 2,000 tests
per hour and 70 reagent positions, doubling the existing clinical
chemistry throughput on cobas pro integrated solutions
- The new cobas ISE neo analytical unit delivers more efficient
ISE testing, reducing hands-on time through automated
maintenance
More information: Media Release, 24 June 2024 |
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail
assay
B-cell lymphoma |
Roche launches new highly sensitive test to more easily
diagnose patients with B-cell lymphoma
- The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay
is the first clinically approved in-situ hybridisation (ISH) test
with the sensitivity to assess the full spectrum of B-cell lymphoma
subtypes
- The test helps differentiate a B-cell cancer from a normal,
reactive immune response, providing diagnostic certainty for
healthcare providers and their patients
- B-cell lymphoma accounts for approximately 85 percent of
non-Hodgkin lymphoma (NHL) cases, which is the tenth most common
cancer worldwide
More information: Media Release, 20 June 2024 |
cobas liat system
Infectious diseases
|
Roche four-in-one molecular test for SARS-CoV-2, Influenza
A/B viruses and RSV receives US FDA Emergency Use
Authorisation
- The test uses highly sensitive PCR technology, requiring only a
single nasal-swab sample to provide rapid, accurate qualitative
detection and differentiation among four of the most prevalent
respiratory viruses for which differential diagnosis can drive
appropriate treatment
- It enables healthcare professionals to make confident clinical
decisions and promptly determine appropriate treatment, with
definitive results reported in just 20 minutes
- It expands Roche’s extensive molecular point-of-care testing
portfolio, offering greater flexibility to meet testing needs amid
evolving regional prevalence of respiratory infections
More information: Media Release, 10 June 2024 |
Tina-quant lipoprotein (a) RxDx
Cardiovascular diseases |
FDA Breakthrough Device Designation for blood test
measuring Lp(a) – a key marker for hereditary cardiovascular
risk
- Approximately one in five people worldwide have elevated Lp(a)
levels, putting them at increased risk of cardiovascular diseases
including myocardial infarction and stroke
- The Tina-quant Lp(a) assay measures lipoprotein (a) in a
person’s bloodstream, and will be made available on Roche’s
installed base of over 90,000 serum work area (SWA) systems
worldwide
- The test was developed in collaboration with Amgen
More information: Media Release, 22 May 2024 |
HPV self-collection solution
Human papillomavirus (HPV)
|
FDA approval for one of the first HPV self-collection
solutions in the US, expanding access and screening options to help
eliminate cervical cancer
- More than half of all US cervical cancer patients are
underscreened, which makes reducing barriers to sample collection
and increasing access to screenings crucial to ultimately helping
eliminate this deadly disease
- Each year in the US, more than 13,000 patients are diagnosed
with cervical cancer and approximately 4,000 die from this
preventable disease, caused by HPV infection
- Roche’s human papillomavirus (HPV) self-collection solution
will improve access to testing by providing women the option to
privately collect their own sample
More information: Media Release, 15 May 2024 |
Diagnostics sales
Sales |
CHF millions |
As % of sales |
% change |
January–June |
2024 |
2023 |
2024 |
2023 |
At CER |
In CHF |
Diagnostics Division |
7,211 |
7,268 |
100.0 |
100.0 |
5 |
-1 |
Customer Areas4 |
|
|
|
|
|
|
Core Lab |
4,069 |
3,935 |
56.4 |
54.1 |
10 |
3 |
Molecular Lab5 |
1,275 |
1,288 |
17.7 |
17.7 |
3 |
-1 |
Near Patient Care6 |
1,097 |
1,358 |
15.2 |
18.7 |
-14 |
-19 |
Pathology Lab |
770 |
687 |
10.7 |
9.5 |
17 |
12 |
Regions |
|
|
|
|
|
|
Europe, Middle East and Africa |
2,431 |
2,456 |
33.7 |
33.8 |
4 |
-1 |
North America5 |
2,163 |
2,110 |
30.0 |
29.0 |
5 |
3 |
Asia-Pacific |
2,102 |
2,205 |
29.2 |
30.3 |
3 |
-5 |
Latin America |
515 |
497 |
7.1 |
6.9 |
16 |
4 |
More information on Roche performance in the first half of
2024:
- Half-Year 2024 Finance Report
- Half-Year 2024 Presentation
- Appendix with Tables
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
References
[1] Unless otherwise stated, all growth rates and comparisons to
the previous year in this document are at constant exchange rates
(CER: average rates 2023) and all total figures quoted are reported
in CHF.
[2] Pharmaceuticals Division base business: excluding COVID-19
medicine Ronapreve.
Diagnostics Division base business: excluding COVID-19-related
products.
[3] Products launched before 2015.
[4] Core Lab: diagnostics solutions in the areas of immunoassays,
clinical chemistry and CustomBiotech.
Molecular Lab: diagnostics solutions for pathogen detection and
monitoring, donor screening, sexual health and genomics, genomic
tumour profiling.
Near Patient Care: diagnostics solutions in emergency rooms,
medical practices and directly with patients, including integrated
personalised diabetes management.
Pathology Lab: diagnostics solutions for tissue biopsies and
companion diagnostics.
[5] Sales in the Molecular Lab customer area include sales from the
Foundation Medicine business which moved under the responsibility
of the Diagnostics Division from the Pharmaceuticals Division
effective 1 January 2024. The comparative information for 2023 has
been restated accordingly.
[6] Sales in the new Near Patient Care customer area include sales
from Diabetes Care and the Point of Care business, both previously
shown as separate customer areas. The comparative information for
2023 has been restated accordingly.
Cautionary statement regarding forward-looking
statements
This document contains certain
forward-looking statements. These forward-looking statements may be
identified by words such as ‘believes’, ‘expects’, ‘anticipates’,
‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or
similar expressions or by discussion of, among other things,
strategy, goals, plans or intentions. Various factors may cause
actual results to differ materially in the future from those
reflected in forward-looking statements contained in this document,
such as: (1) pricing and product initiatives of competitors; (2)
legislative and regulatory developments and economic conditions;
(3) delay or inability in obtaining regulatory approvals or
bringing products to market; (4) fluctuations in currency exchange
rates and general financial market conditions; (5) uncertainties in
the discovery, development or marketing of new products or new uses
of existing products, including without limitation negative results
of clinical trials or research projects, unexpected side effects of
pipeline or marketed products; (6) increased government pricing
pressures; (7) interruptions in production; (8) loss of or
inability to obtain adequate protection for intellectual property
rights; (9) litigation; (10) loss of key executives or other
employees; and (11) adverse publicity and news coverage. The
statement regarding earnings per share growth is not a profit
forecast and should not be interpreted to mean that Roche’s
earnings or earnings per share for this or any subsequent period
will necessarily match or exceed the historical published earnings
or earnings per share of Roche.
Roche Global Media
Relations
Phone: +41 61 688 8888 /
e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58 |
Sileia
Urech Phone: +41 79 935 81 48
|
Nathalie
Altermatt
Phone: +41 79 771 05 25 |
Lorena
Corfas
Phone: +34 620 29 25 51
|
Simon
Goldsborough
Phone: +44 797 32 72 915 |
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Yvette
Petillon
Phone: +41 79 961 92 50 |
Dr
Rebekka Schnell
Phone: +41 79 205 27 03
|
Roche Investor Relations
Dr Bruno
Eschli
Phone: +41 61 68-75284
E-mail: bruno.eschli@roche.com
|
Dr Sabine
Borngräber
Phone: +41 61 68-88027
E-mail: sabine.borngraeber@roche.com |
Dr Birgit
Masjost
Phone: +41 61 68-84814
E-mail: birgit.masjost@roche.com
|
|
Investor Relations North America
Loren
Kalm
Phone: +1 650 225 3217
E-mail: kalm.loren@gene.com
|
|
- 25072024_MR_Roche HY2024_en
- Communications appendix tables_HY 2024_Sales+Results
Roche (LSE:0QQ6)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (LSE:0QQ6)
Historical Stock Chart
From Jul 2023 to Jul 2024